2 news items
Perrigo Reports First Quarter 2024 Financial Results From Continuing Operations
PRGO
7 May 24
the Company's ability to obtain and maintain its regulatory approvals; potential costs and reputational impact of product recalls or sales halts
Perrigo Receives Binding Offer to Divest its HRA Pharma Rare Diseases Business for up to €275 Million
PRGO
25 Apr 24
the Company's ability to obtain and maintain its regulatory approvals; potential costs and reputational impact of product recalls or sales halts
- Prev
- 1
- Next